Danish firm launches cryotherapy venture in US following FDA approval

Portable cryotherapy Hydrozid is now being launched in the US. A sales partner has been found.

Photo: Andrew Kelly/REUTERS / X02844

A brand new FDA approval means Medilink can launch Hydrozid on the world's largest markets for pharmaceutical and medtech products.

"Since 2015, we've experienced tremendous growth, as providers have experienced how easy and convenient Hydrozid is to use, and most importantly, how effective it is in treating warts and other skin conditions," said Christian Kjerulf-Jensen, CEO of Medilink, in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs